Io­n­is bags a $75M mile­stone from Bay­er; In­ven­ti­va gar­ners $51M from IPO

• Io­n­is Phar­ma­ceu­ti­cals $IONS is pick­ing up a $75 mil­lion mile­stone pay­ment from Bay­er re­lat­ed to IO­N­IS-FXIRx. Io­n­is plans to start a Phase IIb study with IO­N­IS-FXIRX in pa­tients with end-stage re­nal dis­ease who are on he­modial­y­sis. “We re­cent­ly com­plet­ed a Phase II study in pa­tients with end-stage re­nal dis­ease on he­modial­y­sis, in which IO­N­IS-FXIRx demon­strat­ed ro­bust re­duc­tions in Fac­tor XI ac­tiv­i­ty and no treat­ment-re­lat­ed ma­jor bleed­ing, ” stat­ed B. Lynne Par­shall, COO at Io­n­is Phar­ma­ceu­ti­cals.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.